In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

The new EU Alliance puts cardiovascular health in the spotlight

European Alliance for Cardiovascular Health

Despite significant progress in recent decades in improving cardiovascular care and reducing mortality rates, the burden of cardiovascular disease (CVD) remains greater than any other disease.

Concerted action is needed to ensure that the voices of those affected are heard by policymakers and that cardiovascular health is given appropriate priority. This is why we have come together just before World Heart Day (29 September) to launch the European Alliance for Cardiovascular Health (EACH).  




Concerned about the current situation, the European Society of Cardiology, the European Heart Network and MedTech Europe invited other European organisations with a strong interest in cardiovascular health to join efforts to raise awareness of the burden of CVD.

This has resulted in the European Alliance for Cardiovascular Health, composed of 15 European organisations that bring together health professionals, patient advocates, industry experts, health insurers, NGOs, and others to ensure that Europe’s response to CVD matches the scale of the collective challenge we face.

Together, we call for resolute action by European decision-makers to improve cardiovascular health through a dedicated EU policy plan.

The burden of cardiovascular disease augmented by the pandemic

The data on the burden of CVD is striking. CVD remains the leading cause of death in the EU contributing to 36% of all deaths compared to 26% for cancer.

CVD impacts people of all ages, with CVD accounting for a significant proportion of premature deaths (CVD mortality before age 65 is 24% in men and 17% in women).

We were aware of this high burden before COVID-19 swept across Europe in 2020. However, the pandemic has exacerbated the CVD epidemic and clearly illustrated the vulnerability of patients with CVD. We know now that the SARS-CoV-2 virus damages the heart and vascular system, and that these mechanisms may explain the extremely high morbidity and mortality in patients with pre-existing CVD and COVID-19.

Others who have apparently recovered from COVID-19 may endure long-term cardiovascular complications, such as heart attack and stroke in the first weeks post-infection and shortness of breath, tachycardias and arrhythmias long term Not to mention the negative impact of the COVID pandemic on care and outcomes of patients with acute cardiac conditions and the postponement or even cancellation of elective diagnostic and therapeutic procedures.

Investing in prevention, early detection, and innovation

One of the challenges we aim to overcome together is to tackle damaging stereotypes. In particular, there is a perception that CVD is only a lifestyle disease. The reality is that there are several cardiovascular conditions that are not caused by lifestyle and there is a strong underlying genetic component that shapes our risk of heart attack and stroke. Other diseases simply occur due to ageing and functional decline. In our opinion, this is often overlooked.

Prevention remains a vital tool in our shared battle against the societal burden of CVD. We must begin to think of spending on primary and secondary prevention, including early detection, as an investment rather than a cost. The cost of doing nothing often turns out to be the most expensive option.

We want to see better and equal patient care and a greater focus on improving the quality of life for those living with CVD. There is a clear need for more investment in research and innovation. And, where new medical technologies and medicines can add value for patients and society, access to innovation should be swift and equitable.

Only by uniting can we ensure that our voices are heard. Our new alliance represents a joint effort to change perceptions, raise awareness and, ultimately, bring better cardiovascular health to patients through better policy and funding.

By combining the knowledge and expertise of all stakeholders in CVD, we hope to bring comprehensive advice and guidance to EU policymakers – and deliver value to society in the process.


The original text was published by MedTech Europe